ACE2 decoy Fc-fusions and bi-specific killer engager (BiKEs) require Fc engagement for in vivo efficacy against SARS-CoV-2
J. K. Dick, D. Hicks, V. D. Krishna, J. A. Sangala, B. T. Zandstra, C. Baehr, J. S. Verbeek, M. S. Cragg, M. C.-J. Cheeran, M. Pravetoni, G. T. Hart
This study shows that Fc receptor engagement is necessary for the efficacy of SARS-CoV-2 therapeutics, including mAbs and BiKEs, and demonstrates the effectiveness of ACE2 decoy Fc-fusions and BiKEs against multiple variants.
bioRxiv · Jun 20, 2024 · PreprintImmunology